The global myasthenia gravis treatment market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising FDA approvals, advancement in new treatment therapies, new product launches, and improvement in surgical procedures are some of the key factors contributing to the growth of the global myasthenia gravis treatment market. Myasthenia gravis is a chronic autoimmune, neuromuscular disorder that leads to weakness in the skeletal muscles. Eyes, face, and swallowing are the most affected muscles. According to the National Center for Biotechnology Information (NCBI), 0.25 and 20 per 1,000,000 population have an annual incidence of myasthenia gravis.

Get Free Sample Copy @ https://www.omrglobal.com/request-sample/myasthenia-gravis-treatment-market

LEO Pharma A/S, Mylan N.V., Bausch Health Companies Inc., Bayer HealthCare AG, Encore Dermatology, Inc., Abbvie Inc., Allergan PLC, Bausch Health Companies Inc., Encore Dermatology Inc., GlaxoSmithKline PLC, Nestle SA, Novartis International AG, Pfizer Inc., and so on are among the key players operating in the global myasthenia gravis treatment market. Mergers and acquisitions, partnerships, collaboration, and strategic agreements among others are the key growth strategies that are being adopted by the major players operating in the market to remain competitive in the market place. Hefty investment in the R&D of new drugs for new product launches is the key strategy adopted by the key players of the global myasthenia gravis treatment market to sustain in the marketplace.

A Full Report of Global Myasthenia Gravis Treatment Market is Available at: https://www.omrglobal.com/industry-reports/myasthenia-gravis-treatment-market

In November 2019, Amneal Pharmaceuticals, Inc. had signed a licensing agreement with Kashiv BioSciences LLC for the development and commercialization of K127 in the US. K127 is an extended-release tablet of pyridostigmine, for the treatment of myasthenia gravis which is used to offer rapid onset and 24-hour coverage for improved symptom control, better tolerability, better compliance, and quality of life to the myasthenia gravis patients. The commercialization of the product is anticipated to drive the growth of the myasthenia gravis treatment market in the US.
In March 2019, Novartis AG had received FDA approval for Mayzent (siponimod) tablets, the first oral drug to treat the secondary progressive autoimmune disorder. In October 2017, Alexion Pharmaceuticals, Inc. had received the US FDA approval for Soliris (eculizumab) as a treatment for adult patients with generalized myasthenia gravis and are anti-acetylcholine receptor (AchR) antibody-positive. In Phase 3 REGAIN trial and its continuing open-label extension trial, Soliris showed therapeutic advantages for patients with anti-AchR antibody-positive who had previously failed immunosuppressive care and continued to experience severe symptoms of the unresolved disease, which could include problems seeing, walking, communicating, chewing, and respiratory.

Global Myasthenia Gravis Treatment Market Segmentation
By Treatment
• Medication
• Cholinesterase Inhibitors
• Corticosteroids
• Immunosuppressants
• Surgery
• Others

By End-User
• Hospitals
• Clinics
• Other

Global Myasthenia Gravis Treatment Market – Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific
• China
• Japan
• India
• Rest of the Asia-Pacific
Rest of the World

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/myasthenia-gravis-treatment-market

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 780-304-0404